Get the Stockscreener App
4.38
22.69%
0.81
Pre-market:
4.39
0.010
+0.23%
Leonabio Inc stock is traded at $4.38, with a volume of 6.25M.
It is up +22.69% in the last 24 hours and down -42.29% over the past month.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
See More
Previous Close:
$3.57
Open:
$3.515
24h Volume:
6.25M
Relative Volume:
37.84
Market Cap:
$41.27M
Revenue:
-
Net Income/Loss:
$-129.41M
P/E Ratio:
-0.1818
EPS:
-24.0922
Net Cash Flow:
$-51.97M
1W Performance:
-12.22%
1M Performance:
-42.29%
6M Performance:
-56.29%
1Y Performance:
+0.00%
1-Day Range:
$3.42
$5.3399
1-Week Range:
$2.21
$5.595
52-Week Range:
$2.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
4.38 | 30.62M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-19-26 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Leonabio Inc Stock (LONA) Latest News
LeonaBio Opens Warrant Exercise Window for New Capital - TipRanks
LeonaBio warrants exercisable could raise $146.2M if fully cash‑exercised - TradingView
LeonaBio Inc. (LONA) Slips 2.30% to $6.79, Drifting Toward Support at $6.45BPI Bear Correction - dars.gov.et
Mizuho Securities Maintains LeonaBio(LONA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com South Africa
LeonaBio to Participate in Cantor Global Healthcare Conference 2026 - Yahoo Finance
LONA Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 37.97% EPS SurpriseEstimate Dispersion - dars.gov.et
Perceptive Advisors LLC Expands LeonaBio Inc (LONA) Stake in Str - GuruFocus
Sermonix Pharmaceuticals Discloses Investment at LeonaBio, Inc. with 36.9% Stake - TradingView
Prefunded warrants drive Sermonix-led LeonaBio (LONA) share shakeup - Stock Titan
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
LeonaBio Reaches Key Phase 3 Enrollment Milestone - TipRanks
Perceptive's LeonaBio (NASDAQ: LONA) stake nears its ownership limit - Stock Titan
Anders Hove reports new passive stake in LeonaBio (LONA) - Stock Titan
LONA Maintained by Mizuho -- Price Target Lowered to $15.00 - GuruFocus
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Nigeria
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), LeonaBio (LONA) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LeonaBio Reports Narrower Quarter Loss as Trial Progresses - sekbernews.id
LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming Milestones - Pulse 2.0
LeonaBio (LONA) Market Close: Closes 3.19% Higher at $7.96 at the Close; Level Check: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotLow Volatility Picks - vinanet.vn
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceWedge Breakout - vinanet.vn
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - Kalkine
LONA Maintained by Citizens -- Price Target Lowered to $17.00 - GuruFocus
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances - Yahoo Finance
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Nigeria
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio - GuruFocus
Citizens lowers LeonaBio stock price target to $17 on valuation By Investing.com - Investing.com Canada
LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade
LeonaBio Narrows Q2 Loss - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan
LeonaBio Q2 net loss widens on higher R&D spending - TradingView
LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative
LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LeonaBio’s lasofoxifene to be featured at breast cancer summit By Investing.com - Investing.com Nigeria
LeonaBio’s lasofoxifene to be featured at breast cancer summit - Investing.com
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer - The Manila Times
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), - GlobeNewswire
LONA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares RiseEarnings Stability Report - careplusvn.com
LONA Q1 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineEPS Growth Report - vinanet.vn
LONA: LeonaBio, Inc.12 Month EPS - Zacks Investment Research
LONA Q1 2026 Earnings: EPS Surprises Positively by 32.16% as Shares Retreat 3.76%Revenue Estimate Trend - dars.gov.et
LeonaBio Inc. (LONA) Slips 2.74% to $7.45 as Biotech Stock Nears Key SupportETF NAV Deviation - careplusvn.com
LeonaBio Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Leonabio Inc Stock (LONA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Leonabio Inc Stock (LONA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
1.48%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):